Palmitoylethanolamide Does Not Affect Recovery from Exercise-Induced Muscle Damage in Healthy Males
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 11 healthy men, in a double-blind crossover design
- Dose used in the study
- 350 mg before a bout of eccentric knee extensor exercise, against placebo
- Duration
- 120 hours after exercise
- What was measured
- Muscle strength, jump height, creatine kinase, muscle soreness and muscle biopsies
What the authors reported
Palmitoylethanolamide did not improve soreness, strength or jump performance, and had no effect on molecular markers of muscle damage or repair. Strength fell by up to about 40% and jump height by about 17% after exercise in both conditions, with the same rise in soreness and creatine kinase.
Limits of this study
11 participants, all men, and a single dose. The result runs against the earlier Mallard 2020 trial, which found lower blood markers but also no difference in soreness. The entry was checked against the abstract only, and funding was not listed in the record.
Source
doi:10.1249/mss.0000000000003517
Entry checked against the abstract and citation held by Crossref, the DOI registry on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.